Leukemia
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Zanubrutinib in Acalabrutinib-Intolerant Patients With B-Cell Malignancies
FEATURING
Mazyar Shadman
- December 18, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ph3 CLL12 Trial - Impact of Ibrutinib on QoL in Pts With Early-Stage, Asymptomatic CLL
FEATURING
Ellinor Goergen
- December 17, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ibrutinib or Acalabrutinib in CLL - Impact of Dose Reduction on Therapy Duration
FEATURING
Mazyar Shadman
- December 17, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ph 3 AMPLIFY - Fixed-Duration Acalabrutinib + Venetoclax +/- Obinutuzumab vs. CIT for 1L CLL
FEATURING
Jennifer Brown
- 1 view
- December 17, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: GLOW Study 64-Month Follow-Up - 1L Ibrutinib + Venetoclax vs. Chlorambucil + Obinutuzumab in Elderly/Frail CLL
FEATURING
Carsten Utoft Niemann
- 1 view
- December 16, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ziftomenib + Ven/Aza in R/R NPM1mut or KMT2A-r AML - Interim KOMET-007 Results
FEATURING
Amir Fathi
- December 16, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Epcoritamab Monotherapy in R/R CLL - Expansion and Optimization Cohort Results From EPCORE CLL-1
FEATURING
Alexey Danilov
- 1 view
- December 16, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Venetoclax + Aza for 1L Younger AML Pts Independent of Fitness for Intensive Therapy
FEATURING
Justin Watts
- 1 view
- December 16, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Acalabrutinib, Venetoclax, Obinutuzumab in a 1L CLL Enriched for High-Risk Disease
FEATURING
Matthew Davids
- 4 views
- December 13, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Clinical Study of Oral Azacitidine and Venetoclax in Newly Diagnosed and R/R AML
FEATURING
Maria Amaya
- 2 views
- December 13, 2024